Savara Inc Amortization of Debt Issuance Costs and Discounts
Savara Inc (SVRA) reported Amortization of Debt Issuance Costs and Discounts of $104.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2017-05-09
- Savara Inc amortization of debt issuance costs and discounts for the quarter ending 2017-03-31 was $104.00K, a 38.46% decline year-over-year.
- Savara Inc amortization of debt issuance costs and discounts for the quarter ending 2016-12-31 was $62.00K, a 60.26% decline year-over-year.
- Savara Inc amortization of debt issuance costs and discounts for the quarter ending 2016-09-30 was $615.00K.
- Savara Inc amortization of debt issuance costs and discounts for the quarter ending 2016-06-30 was $163.00K.
- Savara Inc amortization of debt issuance costs and discounts for fiscal 2016 was $1.01M, a 445.41% increase from fiscal 2015.
- Savara Inc amortization of debt issuance costs and discounts for fiscal 2015 was $185.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2017-03-31 | $104.00K 10-Q · filed 2017-05-09 | $166.00K derived: sum of 2 quarters · filed 2017-05-09 | $781.00K derived: sum of 3 quarters · filed 2017-05-09 | $944.00K derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $677.00K derived: sum of 2 quarters · filed 2017-03-06 | $840.00K derived: sum of 3 quarters · filed 2017-03-06 | $1.01M 10-K · filed 2017-03-06 |
| 2016-09-30 | $615.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $778.00K derived: sum of 2 quarters · filed 2016-11-08 | $947.00K 10-Q · filed 2016-11-08 | $1.10M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-06-30 | $163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $332.00K 10-Q · filed 2016-08-09 | $488.00K derived: sum of 3 quarters · filed 2017-05-09 | |
| 2016-03-31 | $169.00K 10-Q · filed 2017-05-09 | $325.00K derived: sum of 2 quarters · filed 2017-05-09 | ||
| 2015-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $185.00K 10-K · filed 2017-03-06 | ||
| 2015-09-30 | $29.00K 10-Q · filed 2016-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |